After the books closed: the quarter's biggest news happened too late to be in the numbers
The model's full reasoning — Q3 2018 call → NOWe need to determine if management reports that the most important positive developments of the period happened so late in the reported period or shortly after it ended that the results contain little or none of their effect, with management itself marking the timing. Let's analyze the transcript. The call is for Q3 fiscal 2018 (quarter ended around June 30, 2018). The call is on August 6, 2018. Key positive developments mentioned: - Revenue of $22.2M, up 25% over Q3 2017. Includes $1.7M from SurVeil agreement with Abbott. - They updated guidance upward for revenue and non-GAAP EPS. - They mention the Embolitech acquisition in May (during the quarter) which resulted in a charge. - They talk about progress on TRANSCEND trial, SurVeil, etc. - They mention the launch of MatrixGuard Diluent in IVD business. - They mention receiving FDA clearance for .018 peripheral balloon catheter in April (during the quarter). - They mention the Telemark microcatheter received FDA clearance in Q2 fiscal 2018 (so earlier). - They mention progress on BTK and AV fistula programs. Now, the question: Did management report that the most important positive developments happened so late in the period or shortly after it ended that the results contain little or none of their effect? And did management itself mark the timing? Look for phrases like "late in the quarter", "since quarter-end", "subsequent to the close", etc. In the transcript, I see no such explicit timing markers for positive developments. The positive developments are spread across the quarter: revenue growth, Abbott deal (announced in February, revenue recognized in Q3), Embolitech acquisition in May, FDA clearance in April, etc. They don't say "these happened at the very end of the quarter" or "after the quarter ended". They also don't say that the results reflect little or none of these developments. In fact, they raised guidance because of better performance. The only mention of timing is about the Embolitech charge, which is a negative, not a positive. They also mention that R&D expense will accelerate in Q4, but that's not a positive development. They do mention that they expect to file for first human use for BTK/AV in fiscal 2018, but that's future. They also mention that they are progressing towards commercial agreements, but those are not yet signed.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| SWBI | Smith & Wesson Brands, Inc. | Q1 2023 | 2022-09-08 | C+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
OPK · Q1 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management treating the ModeX acquisition (announced and closed on the call date, May 9) and the Sema4/GeneDx deal (closed April 29) as major positive developments that occurred after the Q1 period ended. These are framed as key steps toward unlocking value and are highlighted as the "exciting announcement" that changed the call format.
RNW · Q2 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management explicitly marking the timing of key positive developments: 400 MW commissioned "since the end of the quarter" (bringing operating capacity to 7 GW today, with another 400 MW scheduled "over the next couple of weeks"), plus the completed Telangana acquisition adding 260 MW.
ASM · Q4 2023 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...